168 results about "Cell aggregation" patented technology

The invention relates to the discovery of a selective cell surface marker that permits the selection of a unique subset of pancreatic stems cells having a high propensity to differentiate into insulin producing cells or into insulin producing cell aggregates.

The invention relates to a cervical exfoliated cell preservative liquid, the preservative liquid comprises the following components with the contents (by weight): 20 percent to 50 percent of alcohols; 15 percent to 50 percent of anti-aggregation reagent; 5 percent to 10 percent of buffer solution; 1 percent to 20 percent of ion strength maintaining reagent; 0.01 percent to 0.5 percent of anti-microbial reagent; 0.1 to 5 percent of mucus dissolving reagent; and 0 to 0.5 percent of cleaning agent. Compared with the prior art, the preservative liquid can not only lead cells to maintain the shape in an in vitro liquid suspension environment, minimize the protein precipitation, dissolve larger protein substances, such as blood and mucus, and reduce the cell aggregation, but can also selectively eliminate or reduce red cells, effectively kill microbes, prevent the activity of reverse transcriptase and retain the integrity of nucleic acids and proteins for facilitating the later analysis; in addition, the preservative liquid can greatly reduce the costs of consumptive materials for the TCT detection, improve the sensitivity and the specificity of the cervical cancer screening and accelerate the promotion and the popularization of the TCT technology in a medical system.

The invention is a cell aggregation device comprising a hydrogel substrate having at least one, preferably a plurality, of cell-repellant compartments recessed into the uppermost surface. Each compartment is composed of an upper cell suspension seeding chamber having an open uppermost portion and a bottom portion, and one, or more than one, lower cell aggregation recess connected to the bottom portion of the upper cell suspension seeding chamber by a port. The diameter of the port may be fully contiguous with the walls of the chambers and walls of the recesses, or the diameter of the port may be more narrow than the walls of the chamber but fully contiguous with the walls of the recesses or more narrow than both the walls of the chamber and the walls of the recesses. The upper cell suspension seeding chambers are formed and positioned to funnel the cells into the lower cell aggregation recesses through gravitational force. The aggregation recesses are formed and positioned to promote cellular aggregation by coalescing cells into a finite region of minimum gravitational energy, increasing intercellular contact and minimizing or preventing cell adherence to the substrate. A device for encapsulating aggregates of live cells is provided. The device comprises (i) a biocompatible, bio-sustainable substrate having a cell-encapsulating face composed of one or more biocompatible, bio-sustainable, spaced-apart, cell-encapsulating compartments extending therefrom and (ii) a coating layer composed of a biocompatible, bio-sustainable polymer that completely surrounds the substrate and the cell-encapsulating compartments. A method for making the device is also provided.

A three-dimensional (3-D) culture “Petri-dish” for research in regenerative medicine, biotechnology and clinical translation is described. This 3-D perfusion culture dish is to advance in vitro culture tools from static 2-D to dynamic 3-D perfusion culture. Interwoven hollow fiber capillary membranes divide the “Petri-dish” culture space into a controllable 3-D pattern of different compartments, serving the functions of the organ's larger vasculature. These physically active scaffolds, which can be suitable for cell adhesion or cell aggregate immobilization, offer a supply of cells with high-performance mass exchange including gas supply and under perfusion conditions. In contrast to static and discontinuous medium supply, a dynamic culture can be achieved with continuous or alternating medium supply and integral oxygenation. They provide a more physiologic supply in the cell macro environment, including homeostasis of oxygen, pH, nutrition, soluble factors, and gradients of metabolites for the cells. Also, medium perfusion can be achieved. Consequently the invention was made for cultures at tissue density, especially stem cells and support cells, which strive to create their own stem cell niche.

A method of generating cells predominantly displaying at least one characteristic associated with a cardiac phenotype is disclosed. The method comprises (a) partially dispersing a confluent cultured population of human stem cells, thereby generating a cell population including cell aggregates; (b) subjecting said cell aggregates to culturing conditions suitable for generating embryoid bodies; (c) subjecting said embryoid bodies to culturing conditions suitable for inducing cardiac lineage differentiation in at least a portion of the cells of said embryoid bodies, said culturing conditions suitable for inducing cardiac lineage differentiation including adherence of said embryoid bodies to a surface, and culture, medium supplemented with serum, thereby generating cells predominantly displaying at least one characteristic associated with a cardiac phenotype.

Biocompatible hydrogel capsules encapsulating mammalian cells having a diameter of greater than 1 mm, and optionally a cell free core, are disclosed which have reduced fibrotic overgrowth after implantation in a subject. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject.

A network (100) for replacement of a living tissue, said network is a scaffold-free artificial hollow biological tissue network comprising a plurality of longitudinal multicellular aggregates (11) arranged in a plurality of bioprinted layers (22) which are located on top of one another, further comprising an inner surface (20) and an outer surface (21), wherein at least one of said bioprinted layers (22) is in shape of a planar closed loop such that a conduit for conveying fluids is defined, and said longitudinal multicellular aggregate (11) is a mixture of at least two cell types. Also a method for obtaining said longitudinal multicellular aggregate, and a further method for biomodeling and planning said network are proposed.

An object of the present invention is to provide a cell construct for cell transplantation capable of having a thickness suitable for cell transplantation, preventing the necrosis of transplanted cells, and forming blood vessels in the transplantation site after transplantation. The present invention provides a cell construct for cell transplantation which comprises polymer blocks having biocompatibility and cells of at least one type, wherein the plural polymer blocks are arranged in spaces between the plural cells.

We disclose a particle comprising a matrix coated thereon and having a positive charge, the particle being of a size to allow aggregation of primate or human stem cells attached thereto. The particle may comprise a substantially elongate, cylindrical or rod shaped particle having a longest dimension of between 50 μm and 400 μm, such as about 200 μm. It may have a cross sectional dimension of between 20 μm and 30 μm. The particle may comprise a substantially compact or spherical shaped particle having a size of between about 20 μm and about 120 μm, for example about 65 μm. We also disclose a method of propagating primate or human stem cells, the method comprising: providing first and second primate or human stem cells attached to first and second respective particles, allowing the first primate or human stem cell to contact the second primate or human stem cell to form an aggregate of cells and culturing the aggregate to propagate the primate or human stem cells for at least one passage. A method of propagating human embryonic stem cells (hESCs) in long term suspension culture using microcarriers coated in Matrigel or hyaluronic acid is also disclosed. We also disclose a method for differentiating stem cells.

Viable differentiating cells from in vitro cultures of stem cells are selected for by partial dissociation to provide cell aggregates. Aggregates comprising cells of interest are selected for phenotypic features using methods that substantially maintain the cell to cell contacts in the aggregate.

Providing is cellular aggregates derived from corneal endothelial cells that, when transplanted, readily adhere to the parenchyma of cornea and function in a manner equivalent to corneal endothelial cells, and a method of transplantation of the cellular aggregates. Cellular aggregates derived from corneal endothelial cells. The cellular aggregates derived from corneal endothelial cells is prepared by culturing human corneal endothelial cells in a medium containing fetal bovine serum, growth factor and glucose; and then float culturing the cells obtained in a medium containing growth factor. A method of transplantation into the anterior chamber the cellular aggregate or the cellular aggregate prepared by the above method, comprising inserting a tube into the parenchyma of cornea, introducing the cellular aggregate into the anterior chamber through the inserted tube, and causing the cellular aggregate that has been introduced to adhere to Descemet's membrane by assuming in a downward-facing position.

The invention discloses an aggregated white blood cell segmentation counting system. The system comprises an image acquisition module for dyeing white blood cells in a blood sample, dissolving red blood cells in the blood sample by using red blood cell lysate and acquiring a white blood cell image, an image preprocessing module used for performing image background removal on the white blood cellimage and obtaining an optimal segmentation threshold by using a maximum inter-class variance method and roughly segmenting a white blood cell region, an aggregated cell determination module used forobtaining a coarse segmentation image according to the rough segmentation of the white blood cell region, setting a discriminant function of a cell area and obtaining a multi-cell aggregation region,and an aggregated cell segmentation counting module used for extracting a cytoskeleton in each aggregation region and a gray curve at the cytoskeleton by using a morphological refinement method. According to the invention, by analyzing the gray scale characteristics of various white blood cell areas under a low power microscope, an adaptive threshold function is constructed, while a white blood cell count is obtained, the number of oxyphil cells is obtained, the cells in the aggregation region are quickly and accurately divided and counted, the method is quick and simple and is easy to implement.

The invention concerns a device and a method for concentrating pathogenic germs potentiaily present in blood products or derivatives and for detecting said germs comprising the following steps: (a) subjecting a sample of said blood product to a blood cell aggregating treatment, (b) eliminating the aggregates formed at step (a) by passing the treated sample over a first filter allowing through the contaminating germs but not the cell aggregates, (c) selectively lyzing the residual cells of the filtrate obtained at step (b), (d) recuperating the contaminating germs by passing the lysate of step (c) over a second filter to detect the contaminating germs possibly trapped.

The invention relates to a biological microglia comprising at least two pores having a size adopted to allow cells, cell aggregates, tissue or other biological material to pass through said pores, and one or several slicing beams separating said pores from each other, wherein biological material is split / sliced / cleaved into at least two parts when passing said microgrid, a slicing device, an apparatus comprising said slicing device as well as the use of said microgrid, slicing device and apparatus.

Biomedical devices for implantation with decreased pericapsular fibrotic overgrowth are disclosed. The device includes biocompatible materials and has specific characteristics that allow the device to elicit less of a fibrotic reaction after implantation than the same device lacking one or more of these characteristic that are present on the device. Biocompatible hydrogel capsules encapsulating mammalian cells having a diameter of greater than 1 mm, and optionally a cell free core, are disclosed which have reduced fibrotic overgrowth after implantation in a subject. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject.

A method for reporting the result of cell measurement is provided by the present invention. The method comprises the following steps: a User Equipment (UE) configures cells according to the received connection reconfiguration message of Radio Resource Control (RRC), wherein said connection reconfiguration message of RRC comprises a measurement target and a reported event (101); said UE measures the serving cells aggregation according to said measurement target (102); if at least one cell, in said serving cells aggregation measured by said UE, triggers said reported event, said UE will transmit a measurement report, and said measurement report comprises the measurement result of said serving cells aggregation (103), thus improving the UE performance. A user terminal is also provided by the present invention.

This application discloses alginate microencapsulation-mediated differentiation of embryonic stem cells and use of the stem cell differentiation method for the development of effective treatment of various diseases and disorders. The microencapsulation of embryonic stem (ES) cells results in decreased cell aggregation and enhanced neural lineage differentiation through incorporating the soluble inducer retinoic acid (RA) into the permeable microcapsule system. This application also discloses a micro-encapsulation system for immobilizing mesenchymal stromal cells (MSCs) while sustaining the molecular communication. Thus, the invention provides the use of encapsulated mesenchymal stromal cells in the cellular transplantation therapies. Moreover, the invention provides methods for delivery of encapsulated MSCs into the central nervous system and therapies derived therefrom, such as, the treatment of spinal cord injury (SCI) and other inflammatory conditions.

The invention relates to an integrated system for biological tissue treatment and cell collection. The integrated system comprises three parts, namely a collection container for optionally pre-filling protecting liquid or solid for collecting and storing treated cells or cell aggregates, a sieve chamber for carrying samples and separating cells or cell aggregates from cell tissues or organs, and a roller, wherein a rolling disc of the roller is embedded with a rolling disc elbow board and is connected with a hand spike for exerting power and rotating the rolling disc. The three parts are connected with one another and assembled together through threads and threaded sealing covers. After the cells and the cell aggregates are collected, the collection container is sealed by a full closed cover for storage, and the used sieve chamber and roller can be discarded.

A method of culturing human or mammalian mesenchymal stem cells (MSC) or osteoblastic cells to form corresponding cell aggregates evenly distributed in the culturing medium having a reduced content of cells with fibroblast morphology comprises contacting MSC or OC with a water-soluble cellulose derivative over a period of from 1 day to one or two weeks. Also disclosed are a corresponding aggregates, a culture medium and a pharmaceutical composition, and uses of the aggregate, the culturing medium and the composition.

This invention provides compositions and methods useful for the processing of a tissue sample and the preparation of cells, cell aggregates and / or tissue fragments. The invention provides two-stage filer devices and two-membrane devices. Cell aggregates and / or tissue fragments prepared using such devices and according to methods of the present invention can be used in a variety of assay systems, including, but not limited to, drug validation assays, drug screening assays, proliferation assays, metabolic assays, metastasis assays, angiogenesis assays, binding assays, biochemical assays, cellular assays, genetic assays, and the like.

Provided are means and methods for producing embryoid bodies (EBs) from multi- or pluripotent cells. In particular, a method of generating embryoid bodies (EBs) is described comprising agitation of a liquid suspension culture of multi- or pluripotent cells in a container until generation of cell aggregates, optionally diluting the suspension, and further agitation of the suspension until formation of EBs. Furthermore, the present invention relates to the use of the novel culturing method and EBs obtained thereby for a variety of applications including genomics, diagnostic assays, teratogenic / embryotoxicological and pharmacological assays as well as for the provision of tissue grafts.

This invention provides a new procedure for generating cardiomyocyte lineage cells from embryonic stem cells for use in regenerative medicine. Differentiating by way of embryoid body formation or in serum is no longer required. Instead, the stem cells are plated onto a solid substrate, and differentiated in the presence of select factors and morphogens. After enrichment for cells with the appropriate phenotype, the cells are allowed to cluster into cardiac bodies TM, which are remarkably homogeneous and suitable for the treatment of heart disease.

Multivalent ligands which carry or display at least one recognition element (RE), and preferably a plurality of recognition elements, for binding directly or indirectly to cells or other biological particles or more generally by binding to any biological molecule. The multivalent ligands provided can function for binding or targeting to any biological particle or molecule and particularly to targeting of cells or cell types or viruses, for cell aggregation and for macromolecular assembly of biological macromolecules. The multivalent ligands of this invention are applicable for creating scaffolds (assemblies) of chemical or biological species, including without limitation, antigens, epitopes, ligand binding groups, ligands for cell receptors and various macromolecules. In these scaffolds, the number, spacing, relative positioning and relative orientation of recognition elements can be controlled. The invention also relates to methods for aggregating biological particles and macromolecules and for modulating biological response employing the multivalent ligands provided.

The present invention provides a method for subculturing primate embryonic stem cells, and a method for inducing differentiation of the same cell into a vascular endothelial cell and a blood cell. The present invention provides a method comprising culturing primate embryonic stem cells in a medium containing a protein component without using feeder cells and cytokines in a container coated with an extracellular matrix, detaching colonies of the resulting embryonic stem cells in the presence of a cytodetachment agent, and plating the colonies in the similar medium, and a method comprising culturing primate embryonic stem cells in a serum-containing or not containing medium in the presence of cytokine, adhesion-culturing the resulting embryoid body or embroyid body-analogous cellular aggregate in the presence of a cytokine to obtain specific precursor cells, and separating non-adherent cells and adherent cells from the specific precursor cells to obtain blood cells and vascular endothelial precursor cells.

A cell aggregate culture vessel (1) is a vessel for culturing a cell aggregate. The cell aggregate culture vessel (1) includes a well (21) having a culture space capable of storing the cell aggregate and culture fluid and a tubular body (3) which is disposed on the well on a plane at which the well has an opening and have an inner cavity communicating with the culture space, and one or more communication portion (3a) capable of discharging the culture fluid without allowing passage of the cell aggregate to the outside of the tubular body (3) is formed in a tubular wall of the tubular body (3). The communication portion (3a) may be, for example, a slit having a width of 0.1 mm or larger and 0.5 mm or smaller.

Provided are assays and methods for creating proto-tissues from aggregates of cells. The invention concerns assays and methods useful in tissue engineering and reconstruction techniques, specifically in the formation of macrotissues from microtissues using microtissue pre-culture time as a controlling parameter.

This invention is intended to provide cell aggregates that can reproduce functions of the myocardium, such as the function of beating, and thus are available for myocardial regenerative therapy, and to provide a cell culture support for producing the same.According to this invention, a cell culture support for forming string-shaped cardiomyocyte aggregates, which has a substrate portion having one surface on which at least one linear cell-adherent region is formed is provided.